ArticleJournal of cellular and molecular medicine2025
Clinical Features of HBV-Related HCC in Long-Term NAs-Treated Versus Untreated Patients.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Review
- Clinical Features of HBV-Related HCC in Long-Term NAs-Treated Versus Untreated Patients.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patients who receive long-term anti-hepatitis B virus (HBV) treatment with nucleos(t)ide analogues (NAs) are still at risk for primary hepatocellular carcinoma (HCC). Aim The purpose of this study was to compare clinical features of HBV-related HCC in NA-treated vs. untreated patients. The records of patients who were diagnosed with HCC for the first time at the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between January 1, 2019 and September 31, 2024 were retrospectively reviewed. Patients with chronic HBV (CHB)-related HCC were grouped into the NA-treated group and untreated group. A total of 562 patients with CHB-related HCC were identified and divided into the NA treatment group (n = 146) and the untreated group (n = 416). Patient age was similar between the groups (50.9 ± 10.1 vs. 52.5 ± 12.1 years, p > 0.05). HBV DNA level, alanine aminotransferase (ALT) level and gamma glutamyl transpeptidase (GGT) level were significantly lower in the NA group (all, p < 0.001). Alpha fetoprotein (AFP) level was significantly higher in the untreated group (p < 0.05). However, the HBeAg positive rate was significantly greater in the NA group (27.4% vs. 17.5%, p < 0.05), and79.5% (116/146) of HCCs occurred in the first 5 years of NA treatment. Blood biochemical indexes and AFP values of patients who develop CHB-related HCC after NA treatment are usually normal. However, the high HBeAg seropositive rate in patients treated with NAs requires attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.